MedTrace Logo

Single Ascending Dose Study of MSD-001 in Healthy Participants

NCT06702332 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-09-16

No results posted yet for this study

Summary

The purpose of this Phase 1 single ascending dose (SAD) study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamic profile of MSD-001 when administered orally to healthy adult participants.

Conditions

Interventions

DRUG

MSD-001

MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications

DRUG

Placebo Comparator

Matching Placebo

Sponsors & Collaborators

  • Mindstate Design Labs

    lead INDUSTRY

Principal Investigators

  • Gabriel Jacobs, MD, PhD · Centre for Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-11
Primary Completion
2025-06-19
Completion
2025-07-11
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06702332 on ClinicalTrials.gov